Key result
Lorcainide did not suppress group mean PVDs, with only 33% of patients achieving ≥80% suppression, and showed no significant pharmacokinetic interaction with digoxin.
Why the study?
Does lorcainide reduce premature ventricular depolarizations and interact with digoxin in patients taking digoxin?
Population
12 patients with frequent premature ventricular depolarizations (PVDs) who were taking digoxin
Comparison
Lorcainide 100 mg bid or 100 mg tid for 14 days vs Baseline placebo period
Design
Case_series
Follow-up
14 days
Authors
Loading...
Lorcainide may reduce PVDs in digoxin users without pharmacokinetic interaction; leaves open efficacy and safety in larger trials.
Does lorcainide reduce premature ventricular depolarizations and interact with digoxin in patients taking digoxin?
Lorcainide has unpredictable antiarrhythmic effects and reduced efficacy in patients with heart failure or reduced ejection fraction, without significant pharmacokinetic interaction with digoxin.
Giardina et al. (1987) studied Frequent premature ventricular depolarizations (PVDs) (n=12). Lorcainide vs. Placebo period was evaluated on Greater than or equal to 80% suppression of PVDs. Lorcainide did not suppress group mean PVDs, with only 33% of patients achieving ≥80% suppression, and showed no significant pharmacokinetic interaction with digoxin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: